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Abstract: 
Objectives: There is mixed evidence of association of serotoninergic genes with 
anorexia nervosa (AN), but substantial evidence for the involvement of serotonergic 
mechanisms in appetite control.  This study was designed to investigate possible 
associations between the two subtypes of AN (Restricting-RAN, and Binge-purging–
BPAN) and polymorphisms within 5 genes encoding for proteins involved in the 
serotoninergic system.  
Methods: In order to carry out this investigation we have conducted a case-control 
association study on 226 females meeting the criteria for AN, and 678 matched 
healthy females.   
Results: Our data show a significant association between polymorphisms with the 
gene encoding HTR2A with both AN subtypes, an association between 
polymorphisms within the genes encoding HTR1D and HTR1B with RAN, and an 
association between polymorphisms within the gene encoding HTR2C with BPAN.  
No associations were found for any polymorphisms of the serotonin transporter gene. 
This outcome indicates a substantial and complex inter-relationship between 
serotoninergic genes and AN.   
Conclusions: Given these data we hypothesis that the expression or control of 
expression of several genes of the serotoninergic system, and interactions between 
these genes, could exert considerable influence over the specific symptomatology of 
the subtypes of AN.  
KEY WORDS:  Eating Disorder; Anorexia nervosa; genetics; serotonin; serotonin 
recpetor 
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Introduction: 
 
Anorexia nervosa (AN) is a severely debilitating disorder that affects primarily 
women (Hebebrand et al. 1996,Elfhag and Linne 2005) and has the highest mortality 
rate of any of the psychiatric disorders (Sullivan 1995,Steinhausen 2002).  Occurring 
predominantly during adolescence (Halmi et al. 1979) the disease is characterised by 
a pathological obsession for thinness through the control of eating behaviour. 
Evidence from family and twin studies have suggested that both genetic and 
environmental components contribute to the development of AN (Sokol et al. 
2009,Fairburn et al. 1999,Lilenfeld et al. 1998,Vandereycken and Pierloot 
1981,Garfinkel and Garner 1982).  The genetic component has been estimated 
through meta analysis of twin studies as contributing up to 76% of the susceptibility 
to AN (Treasure and Holland 1990,Klump and Culbert 2007).  Although no large 
pedigree studies showing Mendelian inheritance have been reported to date, and 
despite the existence of a large number of published genetic studies, the genetic 
component of this complex disorder is still far from being understood.  This is likely 
to be due in part to the relatively low prevalence rate of this disorder.  A further 
difficulty could be the existence of separate sub-types of this disorder (American 
Psychiatric Association 1994), which are likely to have somewhat different genetic 
profiles. 
The serotonin theory of satiety was proposed more than 30 years ago (Blundell 1977), 
and subsequent research by many authors has confirmed the main tenets of this 
approach (Blundell and Halford 1998,Halford and Blundell 2000,Halford et al. 2004).  
In general, the release or blockade of re-uptake of serotonin causes an inhibition of 
eating, and drugs such as fenfluramine, fluoxetine and sibutramine have all been 
shown to suppress food intake and cause weight loss in obese people (Halford 
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2006,Van der Ploeg 2000).  Fluoxetine has further more been shown to result in 
reduce rates of relapse after inpatient weight gain in Anorexia nervosa (Kaye et al. 
2001).  Considerable research on the serotonin receptor subtypes has implicated the 
HTR1B and HTR2C subtypes in the suppression of appetite (Park et al. 1999). 
Animal studies have shown that the hypophagia induced by the serotonergic releasing 
drug fenfluramine can be antagonised by a highly selective HTR1B antagonist 
(Simansky and Nicklous 2002) injected directly into the parabrachial nucleus, and by 
pre-treatment with the selective HTR2C antagonist.  The hypophagia induced by the 
sertraline can also be blocked by serotonin antagonists acting on HTR1B and HTR2C 
receptor (Lucki et al. 1988).  In addition the HTR1B receptor agonist significantly 
suppressed food intake and modified satiety (Halford and Blundell 1996), and a 
similar effect was shown by the selective HTR2C receptor agonist (Smith et al. 2006).   
These animal studies were complemented by studies in humans indicating that the 
HTR1B/1D receptor agonist (Sumatriptan) decreases food intake in healthy women 
(Boules et al. 2000).  The preferential HTR2C receptor agonist mCPP induces weight 
loss over a 2 week period in obese subjects (Sargent et al. 1997).  Taken together, 
these studies strongly suggest the involvement of HTR1B and HTR2C receptors in the 
inhibition of food intake.  Transgenic animal studies have shown that the HTR1B and 
HTR2C knock-outs cause over-consumption and weight gain (Clifton et al. 2003). In 
keeping with this body of evidence are specific findings indicating a disturbance of 
serotonin metabolism in eating disorders (Kaye et al. 2005,Kaye 1997).   
 
More broadly, in the eating disorders field the evidence for serotonin dysregulation 
has been intensively reviewed (Brewerton 1995) and several studies have shown an 
alteration of serotonin neurotransmission in AN and Bulimia nervosa even after the 
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restoration of body weight and or recovery (Kaye et al. 1998,Frank et al. 2002).  
Furthermore it has been reported that elevated cerebrospinal fluid concentrations of 5-
hydroxyindoleactic acid (5-HIAA) occur both during and after recovery from AN and 
BN (Kaye et al. 1991).  Studies have gone on to show that in individuals recovered 
from AN and BN exposed to serotonin challenges show altered behavioural responses 
(Frank et al. 2001,Kaye et al. 2003,Smith et al. 1999). The serotonergic pathway has 
been shown to be involved in feeding, satiety, fasting, mood, anxiety, impulsivity, 
addiction, body image, perception and gender (Steiner et al. 1997,Brewerton 1995). 
Given the relationship of these behaviours to phenotypic expression it has been 
argued that there is clear evidence for dysregulation of serotonin systems in anorexia 
nervosa (Jimerson et al. 1990).  The reduced dietary intake of tryptophan is unlikely 
to play a major role in altered serotonin metabolism as tryptophan can be provided 
through tissue catabolism (Favaro et al. 2000). Over 20 years ago dysregulation 
implied an inappropriate release or reuptake of serotonin around the synapse, or 
aberrant 5HIAA levels in the CSF.  However with the discovery of multiple subtypes 
(between 15 and 19 depending on the criteria adopted) of the serotonin receptor 
clustering within 7 separate families, the notion of serotonin dysregulation has 
become more complex and can take many forms. The term dysregulation can now be 
applied to unusual combinations of different subtypes of serotonin receptors with 
serotonin playing a role in complex behaviours through an interaction with multiple 
receptors. Our approach to the understanding of the subtypes of anorexia nervosa is 
based on this receptor model of dysregulation.  
 
Several studies have investigated possible associations between AN and 
polymorphisms within serotoninergic genes. There are multiple reports on the 
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serotonin transporter (SLC6A4) gene and AN (Gorwood et al. 2003). Specifically 
research has focused on a functional polymorphism in the 5‟ regulatory promoter 
region which consists of two common alleles which vary due to a 44 base pair 
insertion (Long L-allele) or deletion (Short S-allele).  In the S-allele form functional 
studies have revealed a reduction in serotonin transporter gene expression and uptake.  
There has been mixed evidence for the association of this polymorphism and anorexia 
nervosa, an initial meta-analysis of 4 studies revealed that there is a moderated yet 
significant association with the S-allele and anorexia nervosa (Gorwood 2004).  A 
more recent meta-analysis of 8 studies further supported the Gorwood study and 
showed a strong association with the S form of SLC6A4 and AN (Lee and Lin 2009).   
A number of studies have examined the role of polymorphisms within the gene 
encoding HTR2A receptors and genetic susceptibility to AN. The HTR2A promoter 
polymorphism -14385G/A has been shown to be associated with susceptibility to AN, 
although this finding is not consistent across all studies.  A meta-analysis of 14 
studies suggests that when all data are combined there is statistically significant 
evidence of an association (Gorwood et al. 2003).  One of the possible explanations 
for the diversity of these findings is that many studies have classified patients with the 
generic diagnosis of AN whereas others have investigated the specific sub-types.  
Since it is likely that different allelic profiles and physiological processes underlie 
each specific sub-type, the use of phenotypic sub-types is likely to be more robust. 
A whole genome linkage study has produced the first report of an association of the 
HTR1D receptor locus with RAN (Bergen et al. 2003).  We have confirmed this 
association (Brown et al. 2007).  Of the 4 studies that have investigated the gene 
encoding the HTR2C receptor, 2 have reported positive associations (Hinney et al. 
1997, Nacmias et al. 1999, Karwautz et al. 2001, Hu et al. 2003). Despite the strong 
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evidence for the involvement of HTR1B receptors in the inhibition of appetite, there 
appear to be no studies on the link between AN and the gene encoding the HTR1B 
receptor (Although it may be associated with low weight in bulimia nervosa (Levitan 
et al. 2001). 
 
Given these data we have hypothesed that polymorphisms within genes encoding 
major components of the serotonergic system play an important role in defining 
genetic susceptibility to AN.  Moreover, it is possible that different patterns of 
serotonin receptor genes could distinguish the restricting from the binge-purging 
subtypes of AN. In the current study we have performed a systematic analysis of 
polymorphisms within the genes encoding for SLC6A4, HTR1B, HTR1D, HTR2A 
and HTR2C in a single cohort of well characterised individuals with DSM-IV sub-
typed AN. 
Methods and Materials: 
Subjects 
226 female Caucasian patients, registered at Yorkshire Centre for Eating Disorders 
(Leeds, UK) between 1998 and 2002. All patients recruited to this study had at some 
point been admitted to the centre for inpatient treatment however at the date of 
completing the study the majority were outpatients (n=176). For each patient 
recruited, 3 female British Caucasian individuals were used as controls (total control 
population n = 678). The control group was selected from a large data base of healthy 
individuals in the general population collected for comparison purposes in genetic 
studies. From this healthy population we selected women who were matched with the 
cases for month and year of birth; therefore there was a good match for age and 
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gender between the cases and controls. In addition the controls did not contain any 
individual with any clinical condition.  Patients were diagnosed according to DSM-IV 
criteria for eating disorders by a consultant psychiatrist during clinical interview 
before being approached to take part in this study.  Diagnosis was confirmed through 
the administration of the structured interview for Anorexia and Bulimia (Fichter et al. 
1991, Fichter and Quadflieg 2001).  Patients were classified into two groups identified 
as restricting AN (RAN) or binge-purge AN (BPAN). For this study patients had to 
meet the diagnostic criteria for current diagnosis (i.e. previous 12 months). We further 
extended this to ensure that no diagnostic crossover had occurred within the last 36 
months, but it should however be noted that in those cases where the patient had less 
than 3 years diagnosis of AN this would not be possible and as such it is likely that 
they may undergo diagnostic crossover within the next few years. Based on this 
analysis of the 226 anorexia nervosa patients 122 were characterised as RAN and 104 
were characterised as BAN. After complete description of the study to each subject, 
written informed consent was obtained.  The study was approved by the Leeds United 
Hospital Trust Ethical Review Committee (submission number 01/085). 
Group Definitions 
Participants were dichotomised according to DSM-IV subtype classification. Reports 
of current age, current weight, lowest and highest weight and age of onset were also 
recorded.  From these data BMIs were calculated (BMI = weight (kg) / height (m)
2
) 
see table 1. 
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Table 1: Mean scores and standard deviation of group descriptive 
 
Current 
BMI 
(kg/m
2
) 
Lowest 
BMI 
(kg/m
2
) 
Highest 
BMI 
(kg/m
2
) 
 
Length of 
ED 
(years) 
 
Current 
Age 
(years) 
Restrict 
(RAN) 
(n = 122) 
16.45 
(±2.55) 
13.53 
(±2.42) 
22.38 
(±2.88) 
10.9  
(±8.06) 
28.6  
(±7.32) 
Binge/Purge 
(BPAN) 
(n = 104) 
18.1 
(±3.49) 
14.5 
 (±2.63) 
24.11 
(±4.11) 
8.00  
(±6.74) 
27.5 
 (±6.40) 
Table of mean BMI for participants divided by AN subtype along with age on 
completion of study and length of time since diagnosis with ED   
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Statistics 
Departure from Hardy-Weinberg Equilibrium (HWE) in the control population was 
assessed for each polymorphism using a chi-square test.  An exact HWE permutation 
test was performed if the HWE chi-square p-value was <0.05 and if at least one 
genotype cell had an expected count <5 (Zaykin et al. 1995).  Polymorphisms with a 
HWE p-value (chi-square or exact) <0.005 in control subjects were excluded from 
analysis. 
For each SNP, testing for association between alleles/genotypes and disease status 
was carried out using the fast Fisher‟s exact test (FET) procedure.  The fast FET 
computes exact p-values for contingency tables using the network algorithm 
developed by Mehta and Patel (1983).  
 
For each SNP two parameters are calculated: (1) an odds ratio (95% CI) for the “at 
risk allele” (the allele that appears more frequently in cases than controls); (2) an odds 
ratio for the “genotype” (determined by identifying the genotype that has the largest 
chi-square value when compared against the other 2 genotypes. For example, if a SNP 
has genotypes AA, Aa and aa, 3 chi-square association tests are performed: (a) AA vs 
Aa+aa, (b) Aa vs AA+aa and (c) aa vs AA+Aa.  If test (a) yields the highest chi-
square value, then an odds ratio is calculated for the AA genotype vs the Aa+aa 
genotypes combined).  In some cases the genotype may result in an increased risk and 
in some cases a decreased risk. Where the odds ratio is below 1 this represents a 
decreased risk and when the odds ratio is above 1 this represents an increased risk.  
The allele data are always presented as the allele which increases the risk. 
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Odds ratios (OR) were constructed for the “at risk allele” and “genotype” according to 
the formula OR =  (n11 * n22 ) / (n12 * n21), where n11 = cases with “at risk 
allele”/”genotype”, n21 = cases without “at risk allele”/”genotype”, n12 = controls with 
“at risk allele”/”genotype”, n22 = controls without “at risk allele”/”genotype”. In order 
to avoid division or multiplication by zero, 0.5 was added to each cell in the 
contingency table. 95% confidence intervals for the ORs were calculated as follows: 
lower limit = OR*exp(-z√v), upper limit= OR*exp(z√v), where z = 97.5th percentile 
of the standard normal distribution and v= s-allele[1/(n11)] + [1/(n12)] + [1/(n21)] + 
[1/(n22)]. 
 
Power of the sample 
The current study examines a population of 226 AN patients and 678 healthy control 
individuals.  This single cohort represents one of the largest AN case-control 
populations studied to date and given a minor allele frequency of 0.1 and an expected 
effect size of between 1.6 and 2.6 this study has power of between 77% and 99% at 
the p=0.05 level. 
Association analysis was performed for each of the described SNPs comparing cases 
versus controls; RAN versus controls; BPAN versus controls; and, RAN versus 
BPAN.  
Multiple testing issues 
 
The current analysis forms part of a much larger study of 42 candidate genes for 
anorexia nervosa (data to be published elsewhere).  In total we tested 176 SNPs for 
association with anorexia nervosa and its subtypes.  Due to the large size of the 
overall study and the number of statistical tests performed, we would expect to see a 
number of associations, with p<0.05, simply by chance.  However, given the complex 
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nature of the disorder, coupled with the nature of a “candidate” gene study, it has been 
impossible to put an exact figure on how many false positives may have been 
generated.  In order to reduce the number of false positives, a semi-conservative  
Bonferroni-type correction has been applied to the data presented here, by correcting 
for the number of genes analyses in the whole study.  After applying this correction 
factor, a p-value of less than 0.00119 would be evidence of a strong significant 
association, a p-value of between 0.01 and 0.00120  would be evidence of a possible 
association. 
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RESULTS 
We identified 3 polymorphisms within the gene for SLC6A4, 3 polymorphisms within 
the gene for HTR1B, 4 polymorphisms within the gene for HTR1D, 10 
polymorphisms within the gene for HTR2A and 15 polymorphisms within the gene 
for HTR2C which had minor allele frequencies of greater than 0.10.  The SNP 
identification number
 
(HGVBASE at http://hgvbase.cgb.ki.se), the NCBI-34 mapping 
position, the region of the associated gene where the polymorphisms maps and the 
observed allele frequency in the control population are all shown in table 2 (available 
online).    
 
 Hardy-Weinberg equilibrium and pairwise linkage disequilibrium 
One SNP was found to be out of HWE in the control population (rs2020934 in the 
gene encoding SLC6A4, HWE p=4.67x10
-9
) and was excluded from further analysis; 
The strength of pairwise linkage disequilibrium (LD) varied across the 10 
polymorphisms within the gene for HTR2A (Figure 1).  Complete linkage 
disequilibrium across each of the loci for HTR1B, HTR1D (Brown et al. 2007) and 
HTR2C was observed in this control population (data not shown). There was no 
evidence of LD between the two remaining polymorphisms for SLC6A4. 
 
Figure 1: Modular D’ values for polymorphisms within the gene encoding 
HTR2A.  There appears no discernable pattern of Linkage Disequilibrium(LD) across 
the gene for HTR2A with only polymorphisms rs582854 and rs2770293 appearing to 
be in strong LD. 
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Association of polymorphisms within the genes encoding, SLC6A4, HTR1B, 
HTR1D, HTR2A and HTR2C 
SLC6A4 
No evidence of association with DSM-IV  sub-grouped AN or with AN as a whole, 
was found in this population with either of the polymorphisms (rs1872924 and 
rs3794809) identified in the serotonin transporter gene (SLC6A4) (Table 3 available 
online). 
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HRT1B 
Both genotype (OR=0.53, 95%CI 0.37-0.78; p=0.0019) and allelic (OR=1.33, 95%CI 
1.07-1.66; p=0.0103) frequencies at the polymorphism rs1213371 of HTR1B show 
significant association in a comparison between cases and controls (Table 4).  There 
was no association with either rs1738538 or rs1145835 (Table 4, additional data of 
non-association available online).  
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Table 4: Results of case:control and subtype association analysis with HTR1B. 
                Genotypic Allelic 
Marker  
Comparison
a
 Genotype
b  
  
Odds Ratio 
(95% CI) p-Value 
At risk 
Allele
 
b
 
Odds Ratio 
(95% CI) 
p-Value 
rs1213371       
Ca / Co CC 0.53(0.37,0.78) 0.002 T 1.33(1.07,1.66) 0.010 
RAN/ Co CC 0.53(0.32,0.86) 0.029 T 1.39(1.04,1.87) 0.029 
BPAN / Co CC 0.55(0.32,0.94) 0.052 T 1.26(0.91,1.74) 0.160 
RAN / BPAN TT 0.84(0.42,1.67) 0.893 C 1.07(0.73,1.56) 0.773 
a 
Ca = Cases (all anorexia nervosa cases); Co = Controls; RAN= Restricting anorexia 
nervosa cases; BPAN= Binge-purging anorexia nervosa cases 
b 
“Genotype" does not represent the at risk genotype . Where the odds ratio is below 1 
then the genotype is estimated to decrease risk; where the odds ratio is above 1 then 
the genotype is estimated to increase risk. 
c The term “at risk allele” refers to the allele that occur more frequently in cases than 
in controls.  In the case of the RAN/BPAN comparison, the RAN subjects are deemed 
„cases‟ and BPAN subjects are deemed „controls‟. 
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HTR2A 
Of the 10 SNPs analysed across the HTR2A gene, 2 were associated with AN. 
Polymorphism rs3742278 was found to be significantly associated at both the 
genotypic (OR=0.60, 95%CI 0.43-0.84; p=0.0003) and allelic (OR=1.65, 95%CI 
1.23-2.22; p=0.0012) levels when comparing all cases with controls.  This possible 
association appears to be specific to the BPAN with significant associations in both 
the genotypic (OR=0.47, 95%CI 0.29-0.75; p=0.0015) (however this fails to meet the 
stringent correction for significance at the p=0.00119 level) and allelic (OR=2.04, 
95%CI 1.37-3.03; p=0.0006) comparisons with BPAN and controls which remains 
significant upon applying the correction for significance (figure 2). 
 
Figure 2: Genotypic & allelic frequency and 95% CI for HTR2A polymorphism 
rs3742278. A significant difference was found in the allelic frequency between cases 
and controls (p=0.0011) there was a trend towards significant difference in the 
genotypic test, however this failed to stand up to the correction factor (p=0.0032).  
When comparing BPAN and controls the frequency of the G allele was significantly 
higher in the BPAN than in the controls (p= 0.0006) This association may to be a 
reflection of the extremely low frequency of the G,G genotype. However there were 
no significant differences when comparing the RAN with controls or with BPAN on 
either genotypic or allelic frequencies. 
 
Polymorphism rs985934 was also significantly different in the control population 
from the case when comparing genotypic frequencies (OR=1.79, 95%CI 1.32-2.44; 
p=0.0007).  This association appears to be driven by an association of RAN compared 
with controls in the genotypic level (OR=2.11, 95%CI 1.38-3.21; p=0.0021) (however 
this fails to meet the stringent correction for significance at the p=0.00119 level)   
(figure 3). 
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Figure 3: Genotypic & allelic frequency and 95% CI for HTR2A polymorphism 
rs985934.  A significant difference was found in the genotypic frequency between 
cases and controls (p=0.0007). The frequency of the C,T genotype was increased in 
anorexia nervosa patients compared with the controls and this finding is 
complemented by a decreased frequency of  T,T genotype in the anorexia nervosa  
population compared with the controls.  In the comparison between RAN and controls 
there was a significant association (p=0.0021) in the genotypic analysis.  There was 
no significant difference when comparing RAN with control by alleles (p=0.495).  
There was no significant differences either when comparing BPAN with control 
(Genotypic p=0.086, allelic p=0.079) there was also no significant differences 
between RAN and BPAN (genotypic p=0.355, allelic p=0.500) 
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Table 5: Results of case:control and subtype association analysis with HTR2A. 
Marker 
 Comparison
a
 
Genotypic Allelic 
Genotyp
e
b
 
Odds Ratio 
(95% CI) 
p-
Value 
At risk 
Allele
 b
 
Odds Ratio p-Value 
rs3742278       
Ca / Co AA 0.60(0.43,0.84) 0.003 G 1.65(1.23,2.22) 0.001 
RAN/ Co AA 0.78(0.47,1.28) 0.487 G 1.28(0.82,2.00) 0.286 
BPAN / Co AA 0.47(0.29,0.75) 0.001 G 2.04(1.37,3.03) 0.001 
RAN / BPAN AA 0.49(0.27,0.87) 0.047 G 1.86(1.13,3.05) 0.018 
rs985934       
Ca / Co CT 1.79 (1.32,2.44) 0.001 C 1.21(0.97,1.51) 0.098 
RAN/ Co CT 2.11(1.38,3.21) 0.002 C 1.11(0.83,1.49) 0.495 
BPAN / Co TT 0.58(0.36,096) 0.086 C 1.34(0.97,1.86) 0.079 
RAN / BPAN CC 1.70(0.79,3.67) 0.355 C 1.14(0.78,1.66) 0.500 
a 
Ca = Cases (all anorexia nervosa cases); Co = Controls; RAN= Restricting anorexia 
nervosa cases; BPAN= Binge-purging anorexia nervosa cases 
b 
“Genotype" does not represent the at risk genotype . Where the odds ratio is below 1 
then the genotype is estimated to decrease risk; where the odds ratio is above 1 then 
the genotype is estimated to increase risk. 
c The term “at risk allele” refers to the allele that occur more frequently in cases than 
in controls.  In the case of the RAN/BPAN comparison, the RAN subjects are deemed 
„cases‟ and BPAN subjects are deemed „controls‟. 
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HTR2C 
Of the 16 SNPs investigated within the gene for HTR2C, 10 were found to be 
significantly associated with BPAN when comparing genotypic frequencies with the 
control population however upon correction for multiple testing only 1 of these 
remained significant this was rs2428720 (OR=0.36, 95%CI 0.20-0.65; p=0.000276) 
(Table 6 full data on all non associated SNPS available online).  
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Table 6: Results of case:control and subtype association analysis with HTR2C. 
 Genotypic Allelic 
Marker  
 Comparison
a
 Genotype
b
 
Odds Ratio 
(95% CI) 
p-Value 
At Risk 
Allele
 b
 
Odds Ratio 
p-
Value 
rs2428720       
Ca / Co GG 0.61(0.43,0.86) 0.001 A 1.06(0.81,1.39) 0.729 
RAN/ Co GG 2.32(0.93,5.77) 0.201 G 1.16(0.81,1.66) 0.453 
BPAN / Co AG 0.36(0.20,0.65) 0.001 A 1.36(0.89,2.08) 0.151 
RAN / BPAN AG 0.47(0.24,0.91) 0.069 A 1.41(0.87,2.29) 0.179 
a 
Ca = Cases (all anorexia nervosa cases); Co = Controls; RAN= Restricting anorexia 
nervosa cases; BPAN= Binge-purging anorexia nervosa cases 
b 
“Genotype" does not represent the at risk genotype . Where the odds ratio is below 1 
then the genotype is estimated to decrease risk; where the odds ratio is above 1 then 
the genotype is estimated to increase risk. 
c The term “at risk allele” refers to the allele that occur more frequently in cases than 
in controls.  In the case of the RAN/BPAN comparison, the RAN subjects are deemed 
„cases‟ and BPAN subjects are deemed „controls‟. 
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Discussion 
The outcome of this investigation has provided evidence for a substantial, and 
complex, interlinking of serotoninergic gene polymorphisms and genetic 
predisposition to subtypes of AN. The findings of the association analysis with 
HTR1D have previously been published (Brown et al. 2007). Significant associations 
have been demonstrated with genes for 4 separate serotoninergic receptors: genetic 
polymorphisms of the HTR1B and HTR1D genes appear to differentiate the RAN 
from control subjects; HTR2C alleles appear to differentiate BPAN from controls; 
and there is allelic variation in the HTR2A gene both within and between BPAN and 
RAN. 
 
A considerable number of previous studies have used the candidate gene approach to 
ascertain the relationship between polymorphisms in the gene encoding HTR2A and 
anorexia nervosa.  Most of these studies have reported no association but in the 
positive studies where DSM-1V classification had been applied, an association was 
reported to relate to the restricting subtype.  In the present study, taking the anorexia 
nervosa group as a whole, a case-control comparison demonstrated a strong 
association (p=0.0007) with a polymorphism within the HTR2A gene.  Moreover, 
whilst there was significant allelic variation between RAN and controls, there was 
also an association shown for BPAN and cases in comparison with controls.  
Consequently we have concluded that considerable allelic variation in polymorphisms 
of the HTR2A gene exists across the whole spectrum of patients with AN.  However, 
the occurrence of differences between restricting and binge-purging anorexia nervosa 
suggests that specific features of this gene not only differ between all anorexia 
nervosa patients and controls but also differ between RAN and BPAN. 
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Of the 10 polymorphisms used to investigate the HTR2A gene, 8 did not demonstrate 
statistically significant associations.  Polymorphism rs3742278 showed significant 
genotype and allelic variation between BPAN and controls (and between cases and 
controls), polymorphism rs985934 demonstrated highly significant genotypic 
association between cases and controls. Therefore, depending upon the specific 
polymorphism chosen in any candidate gene study, an association could be found 
with RAN, BPAN, both subtypes, or neither.  This could account, at least in part, for 
the positive and negative findings of association previously reported in the literature 
(Klump and Gobrogge 2005). We are aware that diagnostic stability (or rigidity as it 
is sometimes called) is an issue and that diagnostic crossover is a feature in this 
disorder.  An attempt to ensure this diagnostic stability was made by requiring 
subtype criteria to have been met for the previous 36 months. However there were 
some cases in which the eating disorder had not been diagnosed for the full 36 months 
and in these cases there would still be the possibility of diagnostic crossover prior to 
recruitment into the study. There would also be the possibility in those cases with 
diagnosis of longer than 36 months that diagnostic crossover had previously occurred. 
It is extremely difficult to eliminate the possibility of cross-over within the lifetime of 
the patient, but we feel that we have certainly eliminated the occurrence of cross-over 
within several years of the inception of this study.  
 
A full genome linkage analysis study (Bergen et al. 2003) has, for the first time, 
implicated the HTR1D gene in AN.  A region of human chromosome 1, incorporating 
this gene, was linked with genetic susceptibility to restricting, but not binge-purging, 
anorexia nervosa.  We have recently provided a replication of these findings (Brown 
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et al. 2007).  Of the 4 polymorphisms within this gene included in the analysis, one 
(rs856510) showed significant genotypic and allelic variation between RAN and 
controls, and a separate polymorphism (rs674386) also showed significant allelic 
variation between RAN and controls.  These findings suggest that further analysis of 
the relationship between this gene and AN is warranted. 
 
There is considerable evidence to implicate the HTR1B and HTR2C receptors in the 
control of appetite, and specifically with an inhibition of eating in animals and 
humans (Blundell and Halford 1998).  There is therefore considerable circumstantial 
evidence for considering that variation in the genes for these 2 receptors could be 
associated with severe forms of human appetite disorders.  There appears to have been 
no previous reports in the literature of association between AN and the HTR1B 
receptor gene.  Of the 3 polymorphisms included in the current genotyping analysis, 
one (rs1213371) showed a significantly different frequency of occurrence in AN 
versus controls, and this was largely due to an association with the RAN subgroup. 
This polymorphism showed significant genotypic and allelic variation with the RAN 
subgroup.  The association between polymorphisms within the gene for the HTR1B 
receptor (exclusively with the restricting subtype) is consistent with the known 
functional activity of this receptor in the appetite control systems.  The HTR1B 
receptor agonist CP-94,253 inhibits food intake and intensifies satiety in rats (Halford 
and Blundell 1996) whilst in humans sumatriptan, which has a high affinity for the 
HTR1B (and HTR1D) receptor, has been shown to reduce intake at a meal (Boeler et 
al. 1997).  Given this evidence, it is plausible to envisage that some adjustment to the 
structure of the HTR1B gene, if this caused a change in levels or sensitivity of 
HTR1B receptors, could promote a tendency to food restriction. 
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In contrast to the association of the HTR1B genes and RAN, a quite different pattern 
was observed for the HTR2C gene.  Here, of the 16 polymorphisms investigated, 10 
were found to be significantly and exclusively associated with the BPAN subtype.  
Moreover, there was also variation of the HTR2C genotypic and or allelic frequencies 
between the RAN and BPAN groups.  Clearly, one reason for the significant 
associations with so many polymorphisms is because these polymorphisms were in 
LD indicating that a sizeable block of this gene is inherited as a complete unit.  There 
is considerable evidence from animal studies that agonism at the HTR2C receptor is a 
sufficient condition for inhibition of food intake (Halford et al. 2004).  Indeed, 
agonists at HTR2C receptors are currently in development as anti-obesity agents 
(Halford et al. 2004).  This account is plausible since the HTR2C receptor agonist has 
been shown to decrease appetite and body weight in obese subjects (Smith et al. 
2006). 
 
In addition the transgenic HTR2C knock-out mouse displays hyperphagic behaviour 
and is obese (Tecott et al. 1995). A further interesting feature is that moderate food 
deprivation causes HTR2C receptor super-sensitivity (Cowen et al. 1996).  Although 
three studies have found no association of the Cys-23-Ser alteration of the HTR2C 
receptor gene and either obese or underweight children (Hinney et al. 1997), anorexia 
nervosa patients (Nacmias et al. 1999), or sib-pair with anorexia nervosa (Karwautz et 
al. 2001) two other studies have reported an association between the Cys-23-Ser 
alteration of the HTR2C gene with low weight in teenage girls (Westberg et al. 2002) 
and minimum body mass index in AN (Hu et al. 2003).  The results of the present 
study support an association but also go further to link the HTR2C receptor gene with 
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BPAN.  In the light of the experimental evidence concerning the HTR2C receptor and 
appetite control, an association between polymorphisms within this gene and AN is 
entirely plausible.  The reason why this gene should be associated exclusively with 
BPAN is not immediately clear.  However there exists the interesting possibility that 
the powerful restriction of food intake in RAN and BPAN patients may be facilitated, 
at least in part, by 2 distinct serotoninergic receptor subtypes; the HTR1B in RAN and 
the HTR2C in BPAN.  However, this suggestion should be treated with caution.  The 
complex relationship between serotonin genes and the expression of appetite, and the 
reciprocal influence of dieting (and nutrition) on the sensitivity of serotonin receptors 
(as discussed by Hu et al. 2003) means that several possible neurochemical scenarios 
could be envisaged to mediate between polymorphisms of a gene for a specific 
receptor and the processes underlying the variability in symptomatology in AN 
patients.  An area for further investigation is the link between tryptophan and 
serotonin and the possible mediating effects of tryptophan in eating disorders (Russo 
et al. 2007). 
 
The outcome of this investigation supports the view that a complex variation in the 
genes from 4 different serotoninergic receptors (HTR1B, HTR1D, HTR2A and 
HTR2C) influences genetic susceptibility across the spectrum of symptomatology in 
AN.  The investigation was driven by a strong hypothesis concerning the relationship 
between receptor sub-types in the serotoninergic systems and the clinical expression 
of sub-types of AN.  We have decided to publish the results for all receptor sub-types 
together, rather than singly in order to provide the fullest picture of the inter-
relationships.  The study had considerable power and the associations (where 
significant) high probabilities.  Some of the associations are complex.  For example 
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with the HTR2A gene different polymorphisms show significant associations when 
comparisons are made between the whole group of AN cases, RAN or BPAN.  This is 
intriguing and suggests that there is a controlling element in this gene relevant to the 
phenotypic expression of anorexia nervosa. For this, and the other associations seen 
for HTR1D, HTR1B and HTR2C genes further interpretation would be pure 
supposition.  Taken as a whole these findings suggest an important relationship 
between serotonin receptor activity and clinical symptoms in AN. 
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Online tables 
 
Table 2: Details of SNPs used in genotyping of SLC6A4, HTR1B, HTR1D, 
HTR2A and HTR2 
 
a 
NCBI v35 identifier, HGVBASE at http://hgvbase.cgb.ki.se, 
b
 According to NCBI 
v35 Map, 
c
 Allele frequencies from control samples 
 
 
 
Gene                     
Marker
a
 
Chrm: 
Position
b
 
Region Flanking Region 
Allele 
Frequency
c
 
SLC6A4     
rs3794809 17:25555384 Intron CTTTATGACT(A>G)TGAAATAATA A: 0.453; G: 0.547 
rs1872924 17:25570472 Intron ATCATAGTCA(C>T)CTAGATTCCT C: 0.209; T: 0.791 
rs2020934 17:25585586 Intron ACCGTTCCAA(T>C)ATGGATGAGT C: 0.472; T: 0.528 
HTR1B     
rs1738538 6:78224175 3‟ Flank ATTTGGAGAC(C>T)CTCTGCCTGA C: 0.865; T: 0.135 
rs1145835 6:78225402 3‟ Flank TTGCAGAATA(G>T)GAAAGCACAA G: 0.069; T: 0.931 
rs1213371 6:78236764 5‟ Flank TGCAGCTGCA(C>T)CTTGGGAAAA C: 0.582; T: 0.418 
HTR1D     
rs604030 1:23263533 3‟ Flank GGTCCCCAGA(G>T)GAACTGTGAG G: 0.634; T: 0.366 
rs652783 1:23259619 Intron TTAATCATCA(T>C)GCTATCCTTA C: 0.365; T: 0.635 
rs674386 1:23267141 5‟ Flank CATCAGGAAA(G>A)AAACCAAATT A: 0.316; G: 0.684 
rs856510 1:23269713 5‟ Flank TGACAAGAAG(A>C)TACCATTTTC A: 0.684; C: 0.316 
HTR2A     
rs3803189 13:46306571 3‟ Flank AAATAGCTAT(A>C)AATAGTGAAA A: 0.860; C: 0.140 
rs977003 13:46313002 Intron TGGTGTAATT(T>G)AGTGCTTATT G: 0.453; T: 0.547 
rs3742278 13:46317578 Intron AAGTGCACAC(G>A)TTGCTTATCA A: 0.873; G: 0.127 
rs643627 13:46326612 Intron GAGCTCTATT(G>A)TGTGCCCCTC A: 0.723; G: 0.277 
rs1928042 13:46335217 Intron TAAAGAGTCA(A>C)AATTGCAGTT A: 0.763; C: 0.237 
rs2770293 13:46336975 Intron GAGTGAGATT(C>T)GTCTTTGCAA C: 0.536; T: 0.464 
rs582854 13:46343878 Intron GCCATACTCA(G>T)CCAGTTAGGT G: 0.538; T: 0.462 
rs985934 13:46353726 Intron AGAATACAAA(C>T)GGAAACTTGA C: 0.386; T: 0.614 
rs2025296 13:46361820 Intron ATGATCTAAC(C>T)TGTTTGCTTC C: 0.918; T: 0.082 
rs2070040 13:46365627 Intron ATCAGTATCA(G>A)CTGGAGAGCT A: 0.452; G: 0.548 
HTR2C     
rs475717 X:113638362 5‟ Flank TATTTACCAC(A>C)GGACATAAAT A: 0.832; C: 0.168 
rs3795182 X:113639798 Intron TCTCTTCCAT(A>G)TTTATAAATT A: 0.829 ; G: 0.171 
rs2376488 X:113651140 Intron TTGGAGTTAA(A>C)TGACCTAAGT A: 0.838; C: 0.162 
rs2041675 X:113665758 Intron TCTGAGTATA(C>T)TAAAAACCAC C: 0.167; T: 0.833 
rs2192371 X:113712819 Intron TAATCTATTA(A>G)TCAAAATGTG A: 0.653; G: 0.347 
rs2069237 X:113742127 Intron AAGTGCAAAA(A>G)CTTTTTTGGC A: 0.165; G: 0.835 
rs2248440 X:113784390 Intron GTTATCTTTT(C>T)ACTAAAATAA C: 0.832; T: 0.168 
rs2428720 X:113796606 Intron CTGATCTTAG(A>G)ACAAGTGCTT A: 0.800; G: 0.200 
rs2428712 X:113810464 Intron CTTCTTTGCA(C>T)TTTCAGAGTG C: 0.835; T: 0.165 
rs2428707 X:113823339 Intron GTAAAGCTAT(G>A)GTTCTAAAAC A: 0.162; G: 0.838 
rs2428698 X:113835653 Intron GACATGGCAC(C>T)TCCAGTACAT C: 0.836; T: 0.164 
rs2428728 X:113847106 Intron AACAATCAAG(G>A)TCACTTCTAA A: 0.164; G: 0.836 
rs2497501 X:113853775 Intron TTCCTATACC(C>T)AACACTTAAT C: 0.162; T: 0.838 
rs1577456 X:113920551 Intron CATGCTACTG(A>C)AAATGACAGG A: 0.834; C: 0.166 
rs1932268 X:113955110 Intron GCCTGCCAGC(C>T)GGTGAGGACG C: 0.165; T: 0.835 
rs1414324 X:113971478 3‟ Flank TTCAGCCAAA(A>G)TCAAATCACA A: 0.169; G: 0.831 
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Table 3: Results of case:control and subtype association analysis with SLC6A4. 
                Genotypic Allelic 
Marker  
Comparison
a
 Genotype
b  
  
Odds Ratio 
(95% CI) p-Value 
At risk 
Allele
 
b
 
Odds Ratio 
(95% CI) 
p-Value 
Rs3794809       
Ca / Co AA 0.82(0.69,1.52) 0.994 G 1.01(0.81,1.27) 0.954 
RAN/ Co GG 0.68(0.42,1.01) 0.920 A 1.00(0.73,1.38) 1.000 
BPAN / Co AG 1.12(0.71,1.77) 0.854 G 1.03(0.75,1.43) 0.869 
RAN / BPAN AA 1.05(0.53,2.09) 1.000 A 1.03(0.70,1.53) 0.920 
Rs1872924       
Ca / Co CC 1.34(0.70,2.60) 0.644 C 1.11(0.86,1.44) 0.421 
RAN/ Co TT 0.76(0.35,1.04) 0.683 C 1.14(0.81,1.61) 0.475 
BPAN / Co CC 1.36(0.53,3.54) 0.827 C 1.08(0.73,1.61) 0.760 
RAN / BPAN CT 0.64(0.37,1.30) 0.593 T 1.20(0.76,1.87) 0.493 
a 
Ca = Cases (all anorexia nervosa cases); Co = Controls; RAN= Restricting anorexia 
nervosa cases; BPAN= Binge-purging anorexia nervosa cases 
b 
“Genotype" does not represent the at risk genotype . Where the odds ratio is below 1 
then the genotype is estimated to decrease risk; where the odds ratio is above 1 then 
the genotype is estimated to increase risk. 
c The term “at risk allele” refers to the allele that occur more frequently in cases than 
in controls.  In the case of the RAN/BPAN comparison, the RAN subjects are deemed 
„cases‟ and BPAN subjects are deemed „controls‟. 
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Table 4: Results of case:control and subtype association analysis with HTR1B. 
                Genotypic Allelic 
Marker  
Comparison
a
 Genotype
b  
  
Odds Ratio 
(95% CI) p-Value 
At risk 
Allele
 
b
 
Odds Ratio 
(95% CI) 
p-Value 
rs1738538       
Ca / Co CT 0.77(0.53,1.1.2) 0.308 C 1.18(0.85,1.64) 0.368 
RAN/ Co CT 0.61(0.36,1.05) 0.046 C 1.29(0.80,2.08) 0.296 
BPAN / Co TT 0.86(0.21,3.57) 1.000 C 1.08(0.68,1.70) 0.818 
RAN / BPAN CC 0.63(0.33,1.19) 0.322 T 1.48(0.83,2.65) 0.232 
rs1145835       
Ca / Co GG 0.63(0.03,12.5) 0.887 T 1.13(0.70,1.81) 0.638 
RAN/ Co TT 1.27(0.60,2.66) 0.583 T 1.25(0.60,2.58) 0.595 
BPAN / Co GG 0.61(0.03,12.5) 0.925 T 1.03(0.56,1.91) 1.000 
RAN / BPAN GT 1.62(0.68,3.88) 0.374 G 1.57(0.67,3.65) 0.390 
rs1213371       
Ca / Co CC 0.53(0.37,0.78) 0.002 T 1.33(1.07,1.66) 0.010 
RAN/ Co CC 0.53(0.32,0.86) 0.029 T 1.39(1.04,1.87) 0.029 
BPAN / Co CC 0.55(0.32,0.94) 0.052 T 1.26(0.91,1.74) 0.160 
RAN / BPAN TT 0.84(0.42,1.67) 0.893 C 1.07(0.73,1.56) 0.773 
a 
Ca = Cases (all anorexia nervosa cases); Co = Controls; RAN= Restricting anorexia 
nervosa cases; BPAN= Binge-purging anorexia nervosa cases 
b 
“Genotype" does not represent the at risk genotype . Where the odds ratio is below 1 
then the genotype is estimated to decrease risk; where the odds ratio is above 1 then 
the genotype is estimated to increase risk. 
c The term “at risk allele” refers to the allele that occur more frequently in cases than 
in controls.  In the case of the RAN/BPAN comparison, the RAN subjects are deemed 
„cases‟ and BPAN subjects are deemed „controls‟. 
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Table 5: Results of case:control and subtype association analysis with HTR2A. 
Marker 
 
Comparison
a
 
Genotypic Allelic 
Genotype
b
 Odds Ratio 
(95% CI) 
p-
Value 
At risk 
Allele
 b
 
Odds Ratio p-Value 
rs3803189       
        Ca / Co AC 0.98(0.68,1.39) 0.981 A 1.02(0.74,1.39) 0.937 
RAN/ Co CC 2.40(0.58,9.84) 0.496 C 1.06(0.69,1.65) 0.822 
BPAN / Co CC 0.26(0.01,4.76) 0.621 A 1.10(0.70,1.71) 0.736 
RAN / BPAN CC 0.16(0.01,3.03) 0.169 C 1.06(0.62,1.83) 0.890 
rs977003       
Ca / Co GT 0.70(0.52,0.95) 0.069 T 1.08(0.87,1.34) 0.507 
RAN/ Co GT 0.73(0.48,1.11) 0.325 T 1.02(0.76,1.37) 0.940 
BPAN / Co GT 0.68(0.43,1.06) 0.180 T 1.16(0.84,1.59) 0.417 
RAN / BPAN TT 1.07(0.62,1.86) 0.969 T 1.06(0.73,1.54) 0.773 
rs3742278       
Ca / Co AA 0.60(0.43,0.84) 0.003 G 1.65(1.23,2.22) 0.001 
RAN/ Co AA 0.78(0.47,1.28) 0.487 G 1.28(0.82,2.00) 0.286 
BPAN / Co AA 0.47(0.29,0.75) 0.001 G 2.04(1.37,3.03) 0.001 
RAN / BPAN AA 0.49(0.27,0.87) 0.047 G 1.86(1.13,3.05) 0.018 
rs643627       
Ca / Co GG 0.62(0.33,1.16) 0.254 A 1.09(0.85,1.39) 0.497 
RAN/ Co AG 1.26(0.82,1.93) 0.515 G 1.02(0.74,1.41) 0.933 
BPAN / Co GG 0.44(0.14,1.36) 0.294 A 1.23(0.85,1.78) 0.271 
RAN / BPAN GG 0.41(0.12,1.43) 0.343 A 1.24(0.81,1.91) 0.328 
rs1928042       
Ca / Co AA 1.15 (0.83,1.58) 0.730 A 1.11(0.85,1.45) 0.457 
RAN/ Co AA 1.50(0.96,2.37) 0.214 A 1.41(0.95,2.08) 0.090 
BPAN / Co AA 0.84(0.53,1.35) 0.736 C 1.16(0.80,1.68) 0.495 
RAN / BPAN AA 0.52(0.30,0.93) 0.048 C 1.81(1.12,2.91) 0.015 
rs2770293       
Ca / Co CC 1.07 (0.76,1.51) 0.938 C 1.03(0.83,1.29) 0.776 
RAN/ Co TT 0.74(0.42,1.27) 0.449 C 1.09(0.80,1.49) 0.579 
BPAN / Co TT 0.71(0.45,1.12) 0.298 T 1.03(0.75,1.42) 0.871 
RAN / BPAN TT 0.68(0.39,1.18) 0.354 T 1.03(0.70,1.52) 0.921 
rs582854       
Ca / Co TT 0.85(0.57,1.23) 0.634 G 1.11(0.89,1.37) 0.379 
RAN/ Co TT 0.69(0.40,0.69) 0.316 G 1.13(0.84,1.52) 0.453 
BPAN / Co TT 0.79(0.51,1.23) 0.536 G 1.08(0.79,1.48) 0.686 
RAN / BPAN TT 0.75(0.44,1.26) 0.566 G 1.00(0.69,1.46) 1.000 
rs985934       
Ca / Co CT 1.79 (1.32,2.44) 0.001 C 1.21(0.97,1.51) 0.098 
RAN/ Co CT 2.11(1.38,3.21) 0.002 C 1.11(0.83,1.49) 0.495 
BPAN / Co TT 0.58(0.36,096) 0.086 C 1.34(0.97,1.86) 0.079 
RAN / CC 1.70(0.79,3.67) 0.355 C 1.14(0.78,1.66) 0.500 
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Marker 
 
Comparison
a
 
Genotypic Allelic 
Genotype
b
 Odds Ratio 
(95% CI) 
p-
Value 
At risk 
Allele
 b
 
Odds Ratio p-Value 
BPAN 
rs2025296       
Ca / Co CT 1.69 (1.15,2.50) 0.025 T 1.45(1.01,2.07) 0.051 
RAN/ Co CT 1.71(1.02,2.86) 0.115 T 1.56(0.98,2.50) 0.071 
BPAN / Co CT 1.68(0.93,3.03) 0.152 T 1.32(0.77,2.28) 0.377 
RAN / BPAN TT 0.40(0.02,10.00) 0.858 C 1.22(0.67,2.22) 0.544 
rs2070040       
Ca / Co GG 1.35 (0.98,1.88) 0.196 G 1.18(0.95,1.48) 0.142 
RAN/ Co AA 0.61(0.33,1.12) 0.159 G 1.34(0.98,1.83) 0.072 
BPAN / Co AG 0.67(0.42,1.05) 0.203 G 1.03(0.75,1.42) 0.870 
RAN / BPAN AA 2.29(1.13,4.67) 0.058 A 1.36(0.92,2.01) 0.138 
a 
Ca = Cases (all anorexia nervosa cases); Co = Controls; RAN= Restricting anorexia 
nervosa cases; BPAN= Binge-purging anorexia nervosa cases 
b 
“Genotype" does not represent the at risk genotype . Where the odds ratio is below 1 
then the genotype is estimated to decrease risk; where the odds ratio is above 1 then 
the genotype is estimated to increase risk. 
c The term “at risk allele” refers to the allele that occur more frequently in cases than 
in controls.  In the case of the RAN/BPAN comparison, the RAN subjects are deemed 
„cases‟ and BPAN subjects are deemed „controls‟. 
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Table 6: Results of case:control and subtype association analysis with HTR2C. 
 Genotypic Allelic 
Marker  
 Comparison
a
 Genotype
b
 
Odds Ratio 
(95% CI) 
p-Value 
At Risk 
Allele
 b
 
Odds Ratio 
p-
Value 
rs475717       
        Ca / Co CC 1.65(0.79,3.43) 0.317 C 1.02(0.76,1.36) 0.941 
RAN/ Co AA 0.81(0.78,1.26) 0.618 C 1.21(0.83,1.77) 0.369 
BPAN / Co AC 0.53(0.30,0.93) 0.036 A 1.21(0.78,1.88) 0.442 
RAN / BPAN AC 0.48(0.25,0.91) 0.068 A 1.43(0.86,2.37) 0.201 
rs3795182       
Ca / Co GG 0.40(0.13,1.25) 0.194 A 1.12(0.82,1.53) 0.486 
RAN/ Co GG 0.26(0.05,1.41) 0.078 A 1.68(1.06,2.68) 0.025 
BPAN / Co AG 1.60(0.98,2.64) 0.183 G 1.32(0.87,2.02) 0.216 
RAN / BPAN AA 0.49(0.26,0.91) 0.047 G 1.84(1.06,3.20) 0.036 
rs2376488       
Ca / Co CC 2.03(0.95,4.33) 0.104 C 1.01(0.75,1.35) 1.000 
RAN/ Co CC 2.03(0.68,6.06) 0.482 C 1.19(0.80,1.76) 0.409 
BPAN / Co AC 0.54(0.30,0.96) 0.050 A 1.20(0.77,1.87) 0.441 
RAN / BPAN AC 0.53(0.28,1.03) 0.163 A 1.33(0.80,2.23) 0.297 
rs2041675       
Ca / Co CC 1.94(0.91,4.12) 0.136 C 1.02(0.76,1.36) 0.941 
RAN/ Co CC 1.65(0.57,4.72) 0.578 C 1.18(0.80,1.72) 0.425 
BPAN / Co CT 0.53(0.30,0.95) 0.031 T 1.17(0.75,1.83) 0.507 
RAN / BPAN CT 0.5(0.26,0.96) 0.096 T 1.37(0.82,2.28) 0.247 
rs2192371       
Ca / Co AG 1.09(0.80,1.47) 0.832 A 1.01(0.81,1.27) 0.954 
RAN/ Co GG 0.55(0.27,1.15) 0.194 A 1.13(0.83,1.54) 0.435 
BPAN / Co AA 1.39(0.75,2.59) 0.579 G 1.13(0.81,1.57) 0.495 
RAN / BPAN AA 2.43(1.05,5.62) 0.070 G 1.20(0.81,1.78) 0.368 
rs2069237       
Ca / Co AA 1.86(0.90,3.81) 0.134 A 1.01(0.76,1.35) 1.000 
RAN/ Co AA 1.86(0.68,5.07) 0.412 A 1.25(0.86,1.83) 0.272 
BPAN / Co AG 0.47(0.26,0.85) 0.020 G 1.31(0.83,2.07) 0.268 
RAN / BPAN AG 0.45(0.23,0.88) 0.057 G 1.51(0.90,2.52) 0.123 
rs2248440       
Ca / Co TT 2.23(1.09,4.59) 0.039 T 1.02(0.77,1.36) 0.883 
RAN/ Co TT 2.07(0.75,5.74) 0.369 T 1.22(0.84,1.78) 0.322 
BPAN / Co CT 0.45(0.25,0.82) 0.007 C 1.22(0.78,1.90) 0.382 
RAN / BPAN CT 0.45(0.23,0.88) 0.051 C 1.39(0.84,2.30) 0.205 
rs2428720       
Ca / Co GG 0.61(0.43,0.86) 0.001 A 1.06(0.81,1.39) 0.729 
RAN/ Co GG 2.32(0.93,5.77) 0.201 G 1.16(0.81,1.66) 0.453 
BPAN / Co AG 0.36(0.20,0.65) 0.001 A 1.36(0.89,2.08) 0.151 
RAN / BPAN AG 0.47(0.24,0.91) 0.069 A 1.41(0.87,2.29) 0.179 
rs2428712       
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 Genotypic Allelic 
Marker  
 Comparison
a
 Genotype
b
 
Odds Ratio 
(95% CI) 
p-Value 
At Risk 
Allele
 b
 
Odds Ratio 
p-
Value 
Ca / Co TT 2.09(1.00,4.36) 0.705 T 1.03(0.77,1.83) 0.880 
RAN/ Co TT 1.79(0.61,5.22) 0.466 T 1.23(0.83,1.82) 0.351 
BPAN / Co CT 0.47(0.26,0.85) 0.009 C 1.20(0.77,1.87) 0.441 
RAN / BPAN CT 0.44(0.23,0.87) 0.048 C 1.37(0.82,2.29) 0.243 
rs2428707       
Ca / Co AA 2.13(0.99,4.60) 0.059 G 1.01(0.76,1.36) 0.940 
RAN/ Co AA 1.73(0.59,5.04) 0.559 A 1.18(0.81,1.73) 0.422 
BPAN / Co AG 0.43(0.23,0.79) 0.004 G 1.29(0.81,2.05) 0.310 
RAN / BPAN AG 0.45(0.22,0.85) 0.040 G 1.46(0.87,2.46) 0.190 
rs2428698       
Ca / Co CT 0.70(0.49,1.02) 0.089 C 1.13(0.83,1.53) 0.448 
RAN/ Co TT 0.96(0.60,1.49) 0.975 C 1.03(0.69,1.53) 0.919 
BPAN / Co TT 0.45(0.25,0.84) 0.010 C 1.26(0.79,2.00) 0.364 
RAN / BPAN CT 0.47(0.24,0.94) 0.048 C 1.22(0.71,2.09) 0.495 
rs2428728       
Ca / Co AA 2.19(1.04,460) 0.048 A 1.01(0.75,1.35) 1.000 
RAN/ Co AA 1.74(0.60,5.08) 0.574 A 1.16(0.79,1.70) 0.485 
BPAN / Co GG 0.46(0.25,0.83) 0.005 G 1.18(0.76,1.84) 0.507 
RAN / BPAN AG 0.45(0.23,0.88) 0.046 G 1.32(0.79,2.19) 0.305 
rs2497501       
Ca / Co TT 0.71(0.50,1.03) 0.054 T 1.05(0.78,1.41) 0.764 
RAN/ Co CC 1.44(0.46,4.51) 0.865 C 1.05(0.76,1.56) 0.839 
BPAN / Co TT 0.47(0.26,0.85) 0.007 T 1.17(0.75,1.82) 0.506 
RAN / BPAN CT 0.50(0.25,0.98) 0.074 T 1.18(0.70,1.98) 0.597 
rs1577456       
Ca / Co CC 2.19(1.04,4.59) 0.043 C 1.00(0.75,1.33) 1.000 
RAN/ Co CC 1.75(0.60,5.10) 0.545 C 1.18(0.80,1.72) 0.424 
BPAN / Co AC 0.45(0.26,0.81) 0.004 A 1.21(0.78,1.88) 0.389 
RAN / BPAN AC 0.47(0.25,0.91) 0.056 A 1.31(0.79,2.17) 0.309 
rs1932268       
Ca / Co CC 2.19(1.04,4.59) 0.042 C 1.00(0.75,1.34) 1.000 
RAN/ Co CC 1.74(0.60,5.08) 0.545 C 1.18(0.81,1.73) 0.423 
BPAN / Co CT 0.43(0.24,0.79) 0.003 T 1.23(0.79,1.91) 0.382 
RAN / BPAN CT 0.43(0.23,0.88) 0.046 T 1.32(0.79,2.19) 0.305 
rs1414324       
Ca / Co AA 2.23(1.12,5.07) 0.055 A 1.09(0.81,1.46) 0.593 
RAN/ Co GG 0.70(0.44,1.11) 0.212 A 1.41(0.95,2.10) 0.110 
BPAN / Co AG 0.43(0.23,0.78) 0.003 G 1.24(0.79,1.93) 0.379 
RAN / BPAN AG 0.40(0.20,0.79) 0.022 G 1.47(0.88,2.47) 0.152 
a 
Ca = Cases (all anorexia nervosa cases); Co = Controls; RAN= Restricting anorexia 
nervosa cases; BPAN= Binge-purging anorexia nervosa cases 
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b 
“Genotype" does not represent the at risk genotype . Where the odds ratio is below 1 
then the genotype is estimated to decrease risk; where the odds ratio is above 1 then 
the genotype is estimated to increase risk. 
c 
The term “at risk allele” refers to the allele that occur more frequently in cases than 
in controls.  In the case of the RAN/BPAN comparison, the RAN subjects are deemed 
„cases‟ and BPAN subjects are deemed „controls‟. 
 
